RxDoctor Payments Data

Akash Patel, MD

Family Medicine · East Bridgewater, MANPI 1609032580

Payments from drug & device makers

$707in general payments, 2019–2025

Across 16 payments — averaging $44.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kestra Medical Technology Services, Inc.$173
  • Medtronic$130
  • Angiodynamics, Inc.$129
  • Sumitomo Pharma America, Inc.$86
  • Novartis$52
  • AstraZeneca$40
  • plus $97 from 4 others

What the payments were for

  • Food & beverage$707100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$707 in reported general payments places this provider in the 80th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$274,520
Medicare patients
786
Services billed
3,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$129,063
OzempicSemaglutide79$91,588
TrulicityDulaglutide74$89,337
JardianceEmpagliflozin65$76,249
MounjaroTirzepatide47$60,357
XareltoRivaroxaban59$56,174
JanuviaSitagliptin Phosphate33$31,526
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$30,997
FarxigaDapagliflozin Propanediol15$23,542
EntrestoSacubitril/Valsartan28$21,613
Breo ElliptaFluticasone/Vilanterol32$21,499
Rosuvastatin Calcium390$15,220
Tresiba Flextouch U-200Insulin Degludec13$14,718
Bydureon BciseExenatide Microspheres12$14,232
Repatha SureclickEvolocumab13$10,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$91,58879 claims
Johnson & JohnsonXarelto$23$56,17459 claims
AstraZenecaFarxiga, Symbicort$40$28,78930 claims
NovartisEntresto$52$21,61328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in East Bridgewater

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →